RxDoctor Payments DataLook up a doctor →

Milan Sanghavi, MD

Neurology · Pasadena, MDNPI 1497967277

Payments from drug & device makers

$144,674in general payments, 2019–2025

Across 1,343 payments — averaging $107.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$53K
  • AbbVie$50K
  • Biohaven Pharmaceutical Holding Company Ltd.$13K
  • Biohaven Pharmaceuticals, Inc.$7K
  • Pfizer$5K
  • Novartis$2K
  • plus $14K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC143$52,738
AbbVie(2 entities)243$50,487
Biohaven Pharmaceutical Holding Company Ltd.32$12,810
Biohaven Pharmaceuticals, Inc.17$6,870
Pfizer31$5,306
Novartis143$1,883
Biogen69$1,240
Lundbeck LLC58$1,001
UCB, Inc.40$962
Sunovion Pharmaceuticals Inc.56$741
Eisai Inc.30$650
Amgen(2 entities)36$622
EMD Serono, Inc.28$577
Teva Pharmaceuticals USA, Inc.37$523
Takeda Pharmaceuticals U.S.A., Inc.16$469
Grifols USA, LLC23$456
Sumitomo Pharma America, Inc.31$430
CSL Behring20$430
Sanofi20$414
AstraZeneca17$375
Jazz Pharmaceuticals Inc.12$333
Acadia Pharmaceuticals Inc17$332
Harmony Biosciences LLC11$331
SK Life Science, Inc.12$309
Argenx US, Inc.10$302
Neurelis, Inc.15$282
Amneal Pharmaceuticals LLC14$274
Neurocrine Biosciences, Inc.8$238
Axsome Therapeutics, Inc.9$210
Bristol Myers Squibb9$207
Catalyst Pharmaceuticals, Inc.9$193
Genentech USA, Inc.8$190
Tanabe Pharma America, Inc.9$186
Banner Life Sciences, LLC9$159
Acorda Therapeutics, Inc6$128
Avanir Pharmaceuticals, Inc.8$117
Johnson & Johnson5$112
Vanda Pharmaceuticals Inc.5$110
Alnylam Pharmaceuticals Inc.4$110
Kyowa Kirin, Inc.5$98
Otsuka America Pharmaceutical, Inc.5$93
Shire North American Group Inc5$90
MDD US Operations, LLC4$88
Adamas Pharmaceuticals, Inc.5$88
Impel Pharmaceuticals Inc.4$87
Upsher-smith Laboratories LLC3$83
GE HealthCare2$64
Kedrion Biopharma, Inc.3$63
Supernus Pharmaceuticals, Inc.2$62
Medtronic1$60
Sanofi-aventis U.S. LLC3$53
Life Molecular Imaging Ltd2$51
Nevro Corp.2$48
Avadel CNS Pharmaceuticals, LLC2$44
Avion Pharmaceuticals2$42
Almatica Pharma LLC2$39
Impel Pharmaceuticals LLC1$36
Currax Pharmaceuticals LLC2$30
ANI Pharmaceuticals, Inc.1$29
Inspire Medical Systems, Inc.1$28

How this compares

$144,674 in reported general payments places this provider in the 85th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$316,583
Medicare patients
714
Services billed
1,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Pasadena

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →